angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
==== Sanctions ==== On 15 September, the company issued a public apology for the contaminated powdered milk; Sanlu was ordered to halt production, and to destroy all unsold and recalled products. Authorities reportedly seized 2,176 tons of powdered milk in Sanlu's warehouses. An estimated 9,000 tons of product had been recalled. Tian Wenhua, chairwoman and general manager of Sanlu and Secretary of the Sanlu Communist Party chapter was stripped of her party and functional posts during an extraordinary meeting of the Hebei provincial standing committee of the CCP; four Shijiazhuang officials, including vice mayor in charge of food and agriculture, Zhang Fawang, were reportedly removed from office. Shijiazhuang Mayor Ji Chuntang resigned on 17 September. Li Changjiang, minister in charge of the AQSIQ, was forced to resign on 22 September after the State Council inquest concluded he was responsible for the "negligence in supervision". Investigators also blamed the Shijiazhuang government. Local Party Secretary Wu Xianguo was fired on the same day.
=== Side effects === Despite its usefulness in experimental studies, 2,6-DCBQ is considered a highly toxic compound, especially as an environmental contaminant formed during the chlorination of drinking water. The primary reason for its toxicity is the generation of reactive oxygen species (ROS), which leads to oxidative stress in cells. This oxidative stress can damage proteins, lipids, DNA, and can also disrupt mitochondrial function, reducing cellular energy production and promoting apoptosis. Exposure to 2,6-DCBQ has been linked to several adverse biological effects. These include neurotoxicity, where the neuronal cell survival and differentiation is impaired, as well as genotoxic effects such as DNA damage and activation of cell-cycle control pathways. Studies in animals have also shown potential kidney damage and inflammatory responses in tissues. Due to its harmful side effects and its presence as a disinfection by-product, 2,6-DCBQ is considered a compound of concern in environmental and toxicological research.
In April 2023, following an investigation by Maryland Attorney General Brian Frosh into child sexual abuse in the Roman Catholic Archdiocese of Baltimore, Attorney General Anthony Brown released a 463-page report accusing the archdiocese of covering up more than 600 cases of child sexual abuse against 156 Catholic priests over 60 years. A week later, Moore signed the Maryland Child Victims Act, which eliminates the statute of limitations on child sexual abuse lawsuits. In April 2025, after state fiscal analysts warned that settling lawsuits involving allegations of sexual abuse against state agencies could cost the state hundreds of millions, if not billions, of dollars, Moore signed into law a bill that lowered the amount of money survivors could win in court. In May 2024, Moore signed into law a bill to ban the sale of speculative tickets and require ticket vendors to provide consumers with the full price of the ticket—including taxes and fees—and refunds if the ticket is counterfeit or if the event is canceled. In May 2025, Moore signed into law a bill establishing the Department of Social and Economic Mobility, a cabinet-level agency to oversee social equity efforts in state government. In October 2025, after a 16-year-old girl committed suicide while under supervision of the state's foster care system and a state audit found 280 instances of children in foster care being placed in hotels, Moore called for reforms to the state's foster care system. He also blamed his predecessor, Larry Hogan, for problems at the Maryland Department of Human Services.
Sources: en.wikipedia.org
Recently, Ke et al. developed a NanoVelcro chip that captures the CTCs from the blood samples. When blood is passed through the chip, the nanofibers coated with protein antibodies bind to the proteins expressed on the surface of cancer cells and act like Velcro to trap CTCs for analysis. The NanoVelcro CTC assays underwent three generations of development. The first generation NanoVelcro Chip was created for CTC enumeration for cancer prognosis, staging, and dynamic monitoring. The second generation NanoVelcro-LCM was developed for single-cell CTC isolation. The individually isolated CTCs can be subjected to single-CTC genotyping. The third generation Thermoresponsive Chip allowed for CTC purification. The nanofiber polymer brushes undergo temperature-dependent conformational changes to capture and release CTCs.
== Function == This protein is a member of the serpin superfamily of serine proteinase inhibitors. Its expression is induced by heat shock. HSP47 is expressed in the endoplasmic reticulum. These cells synthesize and secrete type I and type II collagen. The protein localizes to the endoplasmic reticulum lumen and binds collagen; thus it is thought to be a molecular chaperone involved in the maturation of collagen molecules. HSP47 is essential for the correct folding of procollagen. Antibodies directed to this protein have been found in patients with rheumatoid arthritis.
The company laid off an unspecified number of staffers in March 2005, although Kudirka denied rumors that the company was closing. He soon dissolved 2015 and moved to Florida, returning to Tulsa when he realized he wanted to continue working on video games. Konami Digital Entertainment released Time Ace, developed under the Trainwreck Studios name, in June 2007. On September 24, 2008, Kudirka announced that 2015 had received "several million dollars" in funding from private investors, with which it opened another division, Tornado Studios. The new studio started out with two people, including Kudirka, and sought to make casual games, including for the Wii. At the same time, 2015 was to continue making action games. By March 2009, Tornado Studios had 15 employees and was nearing the release of its first game, Powerbike, through Majesco. The game was released in April under the Trainwreck Studios name. Its first game was Project Runway, initially called World of Fashion until Atari signed to publish it and licensed the series's name. It was released in March 2010. In November, Tornado Studios released Fun with Death for iOS devices. Kudirka said that the rise of digital distribution allowed Tornado Studios to self-publish its games, aiming to release as many games as possible. A third game, Anomaly for personal computers and for the PlayStation 3 via PlayStation Network, was two-thirds-complete by this time and scheduled to be released by April 1, 2011. Tornado Studios had 25 employees, including contractors, at this time.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.